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Information on blinding is part of the data that should be provided upon registration of a trial at a clinical trials
registry. Reporting of blinding is often absent or of low quality in published articles of clinical trials. This study
researched the presence and quality of information on blinding in registered records of clinical trials and highlights
the important role of data-recording formats at clinical trial registries in ensuring high-quality registration.
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The International Clinical Trials Registry Platform
(ICTRP) at the World Health Organization (WHO) pro-
vides a single point of access to information on more
than 200.000 clinical trials made available by registries
around the world [1]. To set a standard for the quality
of entries in registered records, the WHO Trial Registra-
tion Data Set was established, defining the minimum
amount of trial information that must appear in a record
[2]. Part of the information that is required on study de-
sign consists of information on whether blinding was
used and, if so, who was blinded.
We recently reported on the quality of information in
a random sample of registered records of clinical trials
taken from the ICTRP [3]. In this report, we outline the
inconsistencies that we encountered in the use of blind-
ing terminology and highlight the important role of
data-recording formats in attaining high-quality trial
registration.Findings
Our previous study analyzed 731 registered records of
clinical trials that were registered between 17 June 2008
and 17 June 2009 at one of nine clinical trial registries
around the world [3]. This sample was acquired by* Correspondence: rikviergever@gmail.com
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We report here on the same sample, with the exception
that single-arm trials were excluded because they lacked
relevance to blinding. The presence and quality of infor-
mation on blinding was assessed for 571 records.
For each registered record we denoted: 1) whether
there was information on blinding in the registered rec-
ord; 2). whether the record reported a blinding label and
if so, what the blinding label was; and 3) whether the
record mentioned who was blinded in the trial, and if so,
which groups of individuals were blinded.
Of the 571 records in our study sample, 43 (8%) did
not contain any information on blinding, and 212
records (37%) were of trials where there was no blinding
(open-label). Of the 316 records (55%) that reported that
participants were blinded as part of the trial, 48 records
(15%) reported only blinding labels (single-blind, double-
blind), 8 (3%) contained information only on who was
blinded, and 260 (82%) reported both.
For the 260 records for which both blinding labels and
information on who was blinded were present, blinding
labels were cross-tabulated with who was blinded
(Table 1).
Data-recording formats for blinding varied across the
registries (Figure 1). Records from one of the three regis-
tries with free text fields for blinding or study design
were less likely to contain any information on blinding,
compared with registries that requested information on
who was blinded or that requested a blinding label
(OR = 23, 95% CI 11 to 48, χ2 = 123, P<0.001). Records
from one of the three registries that specifically asked forCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Data recording formats for information on blinding at the n
blinded by asking for the blinding status of specific groups of individuals. T
differed per registry. 1One registry requested both information on groups a
Table 1 Trialists’ interpretations of the terms ‘single-
blind’ and ‘double-blind’a
Who was mentioned as blinded Trial was labelled as
Single-blind Double-blind
Patient, caregiver, data analyst /
investigator, outcomes assessor
0 79






Patient, data analyst / investigator,
outcomes assessor
0 9
Caregiver, data analyst / investigator,
outcomes assessor
0 1
Data analyst / investigator,
outcomes assessor
0 1
Patient, outcomes assessor 0 12
Patient, data analyst / investigator 1 68
Patient, caregiver 0 3
Outcomes assessor 22 0




aRecords that contained both blinding labels and information on who was
blinded mainly originated from two registries. One registry asked for
information on the blinding status of subjects, clinicians or therapists,
outcome assessors and/or data analysts. The other registry asked for
information on the blinding status of subjects, caregivers, outcome assessors
and/or investigators. Because of the similarity between these two
classifications, for this table, trials that were labeled to the fourth category of
‘data analysts’ on one registry and ‘investigators’ on the other were
categorized as the same group.
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contain this information, compared with records from
registries that only asked for a blinding label or had a
free-text field for blinding or study design (OR = 719,
95% CI 91 to 5664, χ2 = 205, P<0.001).
Discussion
Information on blinding is often not provided in pub-
lished articles of clinical trials [4], and many trials re-
main unpublished [5]. Clinical trial protocols offer the
most complete resource of information on the study
design of trials [6]. Given the current absence of open
access to clinical trial protocols, the only other source of
information on study design that is publicly available is
the registered record of the trial. It is therefore import-
ant that information on blinding can be found in the
study-design descriptions of registered records of trials.
This study shows that this is not always the case. In
addition, the sole use of the terms ‘single blinding’ and
‘double blinding’ was found to be common, despite the
lack of clarity on their exact meaning. It is a confirm-
ation that these labels should not be used alone, but
should be accompanied by information on who was
blinded [7-9].
Until recently, the groups of individuals that can po-
tentially introduce a bias into a trial through knowledge
of treatment assignments were not clearly defined. The
groups on which the registries in our study requested in-
formation were not consistent (Figure 1). The 2010 revi-
sion to the Consolidated Standards of Reporting Trials
(CONSORT) statement has created considerable clarity
on this issue by defining five possible groups of peopleine registries. Three registries requested information on who was
he groups of individuals about which information was requested
nd a blinding label.
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providers, data collectors, outcome adjudicators, and
data analysts (See Additional file 1; taken from the
CONSORT 2010 statement) [10]. The widespread use of
these definitions by clinical trial registries would im-
prove the quality and interpretability of information on
blinding across clinical trial records from different
registries.
More generally, our findings confirm the pivotal role
for data recording formats at clinical trial registries in
attaining high quality information in registered records
of clinical trials [3,11]. The ICTRP has recognized this
and has recently initiated the establishment of Inter-
national Standards for Clinical Trial Registries. The aim
of these standards is to improve the quality of registered
data by establishing a minimum requirement for quality
control processes performed and data recording prac-
tices used by individual clinical trial registries. It is im-
portant that the quality of registered trial information
continues to be monitored, especially after the introduc-
tion of these standards.
Additional file
Additional file 1: Item 11a of the CONSORT 2010 statement reads:
‘Box 4, on blinding terminology, defines the groups of individuals
(that is, participants, healthcare providers, data collectors, outcome
adjudicators, and data analysts) who can potentially introduce bias
into a trial through knowledge of the treatment assignments.’ [10].
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